TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01047475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB-6
Description: 6# TID with meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6# TID with meal
Study: NCT01958762

Intervention type: OTHER
Group type: OTHER
Intervention: Invitation for oral cavity cancer screening
Study: NCT03923361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprivan
Description: Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.
Study: NCT02565355

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Exclusion
Description: The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
Study: NCT01349413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Oral Esomeprazole 20mg daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo
Study: NCT02272647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone - Acetate
Study: NCT01948492

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein intake
Description: On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
Study: NCT02272647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: (in lieu of Medroxyprogesterone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: (in lieu of Medroxyprogesterone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: (in lieu of Medroxyprogesterone)
Study: NCT01757392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candida albicans Skin Test Antigen
Description: 0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
Study: NCT03763318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EQ001
Description: Itolizumab \[Bmab 600\])

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EQ001
Description: Itolizumab \[Bmab 600\])

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: EQ001 Placebo
Description: EQ001 Placebo
Study: NCT04935411

Intervention type: OTHER
Intervention: nAMD
Description: patients diagnosed with Neovascular Age-Related Macular Degeneration
Study: NCT01517854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 20 mg Revatio (sildenafil citrate) three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to Revatio (sildenafil citrate) three times a day
Study: NCT05458635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right heart catheter
Description: Right heart catheterization was performed for 4 cases with high probability of pulmonary hypertension using multi-lumen swan ganz catheter.
Study: NCT02662803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensive aerobe exercise
Description: Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low-intensive aerobe exercise
Description: Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
Study: NCT03100565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: local lidocaine spray
Description: The lidocaine spray will be introduced to the cervix just before the biopsy procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: forced coughing
Description: The patients will be asked to forced coughing during the biopsy procedure
Study: NCT00960102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cochlear implant
Description: Multichannel Nucleus cochlear implant
Study: NCT00158184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone 15 mg
Description: 15 mg/70 kg oxycodone administered once per day, orally.
Study: NCT00960102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cochlear implant
Description: Multichannel Nucleus cochlear implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid
Description: Phonak hearing aid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid
Description: Phonak hearing aid
Study: NCT02357043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dario Blood Glucose Monitoring System
Description: Finger-stick obtained with BGMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI
Description: Finger-stick sample obtained by nurse/technician to be tested with YSI
Study: NCT02406313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTS
Description: Standardized Thermal Cure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTS
Description: Standardized Thermal Cure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ETP
Description: Patient Therapeutic Education
Study: NCT03577808

Intervention type: OTHER
Intervention: Biopsy
Description: Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
Study: NCT01471158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Description: Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Description: Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
Description: Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide/timolol Maleate Fixed Combination (COSOPT)
Description: Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 500 subcutaneous
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
Study: NCT00158184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone 15 mg
Description: 15 mg/70 kg oxycodone administered once per day, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone 30 mg
Description: 30 mg/70 kg oxycodone administered once per day, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone 30 mg
Description: 30 mg/70 kg oxycodone administered once per day, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 0 mg
Description: 0 mg placebo dose administered once a day, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 0 mg
Description: 0 mg placebo dose administered once a day, orally.
Study: NCT02060422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Description: Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Social support group
Description: Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
Study: NCT02335684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF-LVAD pump speed baseline.
Description: Submaximal exercise test with baseline pump speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CF-LVAD pump speed increased.
Description: Submaximal exercise test with increased pump speed (+800RPM).
Study: NCT02862769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: . Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: . Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
Study: NCT02595242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
Study: NCT03284450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPFT
Description: The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSRS
Description: The SSRS (Howatson \& Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
Study: NCT04621903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shanshamani Vati Plus
Description: Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
Study: NCT01608334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: 1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
Study: NCT01612234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High palmitate or high oleate diet.
Description: High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High palmitate or high oleate diet.
Description: High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
Study: NCT01021566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined hemoperfusion-hemodialysis
Description: Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
Study: NCT05379751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation free Spigelian hernia repair with tentacle mesh
Description: Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
Study: NCT00929240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
Study: NCT04078022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 Shigella Vaccine
Description: 0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 Shigella Vaccine
Description: 0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 Shigella Vaccine
Description: 0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 Shigella Vaccine
Description: 0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 1000 subcutaneous
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
Study: NCT04148872

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Retraining + Chemodenervation
Description: Participants will receive both interventions for the last 4 months of their time on study.
Study: NCT01037088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mild dose cannabis
Description: 3.53% THC by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cannabis
Description: 1.29% THC by weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: 0.00% THC by weight
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 3000 subcutaneous
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 5000 subcutaneous
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml subcutaneous
Study: NCT01700868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association guidelines
Description: Participants will follow individualized diet plans following ADA guidelines
Study: NCT02338336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nowarta110
Description: Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nowarta110
Description: Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nowarta110
Description: Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo liquid for topic administration.
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 500 sublingual
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 mTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 1000 sublingual
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 1000 mTU (Mannosylated Therapeutic Units)/ml sublingual
Study: NCT03934814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ011133
Description: TJ011133 will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ011133
Description: TJ011133 will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ011133
Description: TJ011133 will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ011133
Description: TJ011133 will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks.
Study: NCT02654223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 3000 sublingual
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 3000 mTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG56 Mannosylated 5000 sublingual
Description: Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 5000 mTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group
Study: NCT03934814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered weekly for 5 doses, then followed by monthly doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered weekly for 5 doses, then followed by monthly doses.